Pfizer Says First Patient Dosed in Phase 3 Prostate-Cancer Trial
June 23 2021 - 7:13AM
Dow Jones News
By Matt Grossman
Pfizer Inc. said Wednesday that the first patient has been dosed
in a Phase 3 trial of the use of its talazoparib drug as a
treatment for men with a form of prostate cancer.
The trial will test the use of talazoparib plus enzalutamide,
comparing that combination against a placebo plus enzalutamide. It
will enroll about 550 men with a form of prostate cancer that
includes DNA damage response gene mutations. Men with that form of
the cancer have poorer outcomes than others with prostate cancer,
Pfizer said. The primary endpoint of the study is radiographic
progression-free survival.
Talazoparib is already approved under brand name Talzenna for
treating adults with a form of breast cancer.
Write to Matt Grossman at matt.grossman@wsj.com
(END) Dow Jones Newswires
June 23, 2021 07:10 ET (11:10 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
Pfizer (NYSE:PFE)
Historical Stock Chart
From Aug 2024 to Sep 2024
Pfizer (NYSE:PFE)
Historical Stock Chart
From Sep 2023 to Sep 2024